Dr. Reddy's Laboratories delivered a sharp margin recovery and beat profit expectations despite largely in-line revenue. Brokerages highlighted operating efficiencies and a stronger product mix, while identifying semaglutide supplies and abatacept approval as key catalysts for the coming quarters.
Dr. Reddy's Laboratories delivered a sharp margin recovery and beat profit expectations despite largely in-line revenue. Brokerages highlighted operating efficiencies and a stronger product mix, while identifying semaglutide supplies and abatacept approval as key catalysts for the coming quarters.
<iframe src="https://hindustansphere.com/embed/cluster/1c1dfc49244f42f8fcb7a6a2273c700187806c3b" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Dr Reddy's Q2 Review: Brokerages Flag Margin Recovery As Key Growth Driver — Check Target Price, Potential Upside"></iframe>
